Denali Therapeutics
DNLI
114 hedge funds and large institutions have $1.6B invested in Denali Therapeutics in 2019 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 38 increasing their positions, 26 reducing their positions, and 7 closing their positions.
2,300% more call options, than puts
Call options by funds: $48K | Put options by funds: $2K
343% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 7
46% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 26
27% more funds holding
Funds holding: 90 → 114 (+24)
14% more capital invested
Capital invested by funds: $1.41B → $1.6B (+$198M)
0.8% more ownership
Funds ownership: 71.72% → 72.52% (+0.8%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$16.2M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$12M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$5.3M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$4.55M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$19.1M |
| 2 |
JRP
Jasper Ridge Partners
Menlo Park,
California
|
-$5.81M |
| 3 |
BCM
Bratton Capital Management
Fort Worth,
Texas
|
-$3.32M |
| 4 |
CANY
Caxton Associates (New York)
New York
|
-$2.77M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
-$2.67M |
DNLI Hedge Fund Activity: Q1 2019 in Review
114 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q1 2019, worth a combined $1.6B — up 14% from $1.41B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new DNLI positions and 7 closed out — a net gain of 24 holders — while 38 added to existing stakes and 26 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $16.2M. The largest seller was Flagship Pioneering, cutting an estimated $19.1M.
- 114 institutional investors held Denali Therapeutics (DNLI) as of Q1 2019, up from 90 in Q4 2018.
- Funds reported $1.6B of Denali Therapeutics stock for Q1 2019, up 14% quarter-over-quarter.
- 31 funds opened new Denali Therapeutics positions in Q1 2019 and 7 closed out, a net change of +24 holders.
- The largest Denali Therapeutics buyer in Q1 2019 was Wasatch Advisors, an estimated $16.2M added.
- The largest Denali Therapeutics seller in Q1 2019 was Flagship Pioneering, an estimated $19.1M sold.
Based on aggregated 13F filings for Q1 2019.